Q1 2019 Highlights
-
Total revenue, including royalty and other revenue, was $231.7 million;
-
Product revenue increased 12.8% to $230.5 million, or 14.3% on a
constant currency basis;
-
Shipments of noninvasive technology boards and monitors increased
18.8% to 63,700;
-
GAAP net income per diluted share was $0.87; and
-
Non-GAAP net income per diluted share increased 23.4% to $0.79.
IRVINE, Calif.--(BUSINESS WIRE)--May 6, 2019--
Masimo (Nasdaq: MASI) today announced its financial results for the
first quarter ended March 30, 2019.
First Quarter 2019 Results:
Total revenue, including royalty and other revenue, was $231.7 million.
Product revenue increased 12.8% to $230.5 million, or 14.3% on a
constant currency basis. Shipments of noninvasive technology boards and
monitors increased approximately 18.8% to 63,700 in the first quarter of
2019, compared to 53,600 in the first quarter of 2018.
GAAP operating margin was 24.2%. Non-GAAP operating margin increased 160
basis points to 24.0%, compared to 22.4% in the prior year period.
For the first quarter of 2019, GAAP net income was $49.3 million or
$0.87 per diluted share. Non-GAAP net income per diluted share increased
23.4% to $0.79 per diluted share, compared to $0.64 per diluted share in
the prior year period.
Total cash and short-term investments increased by $40.4 million during
the quarter to reach $592.9 million as of March 30, 2019.
As a result of the strong performance in the first quarter, Masimo is
raising its guidance for fiscal year 2019. The Company now expects
product revenues of $918.0 million, which reflects reported growth of
10.6% and constant currency growth of 11.4%. Masimo is also raising its
GAAP EPS guidance to $3.25 and its non-GAAP EPS guidance to $3.12.
Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “We’re
off to a great start to 2019 and we are happy to report first quarter
results that once again exceeded expectations. Our first quarter results
illustrate the strength of our global business. Our product revenue
increased 14.3% on a constant currency basis to reach $230.5 million,
while we had record worldwide shipments of 63,700 noninvasive technology
boards and monitors. While we are enabling more customers to improve
their patient care and simultaneously helping them reduce their cost of
care, our clinical leading noninvasive monitoring technologies are the
driving force behind our financial success. As we celebrate our 30th
anniversary, we are delighted to be able raise our revenue and earnings
guidance for 2019.”
2019 Financial Guidance
The Company provided the following updated estimates for its full year
2019 guidance:
|
|
2019 Updated Guidance(1) |
|
Prior 2019 Guidance(1) |
| (in millions, except percentages and earnings per share) |
|
GAAP |
|
Non-GAAP |
|
GAAP |
|
Non-GAAP |
|
Total revenue
|
|
$
|
919.1
|
|
|
$
|
918.0
|
|
|
$
|
912.0
|
|
|
$
|
912.0
|
|
|
Product revenue
|
|
$
|
918.0
|
|
|
$
|
918.0
|
|
|
$
|
912.0
|
|
|
$
|
912.0
|
|
|
Percentage growth - as reported
|
|
|
10.6
|
%
|
|
|
10.6
|
%
|
|
|
9.9
|
%
|
|
|
9.9
|
%
|
|
Percentage growth - constant currency
|
|
|
N/A
|
|
|
|
11.4
|
%
|
|
|
N/A
|
|
|
|
10.7
|
%
|
|
Royalty and other revenue
|
|
$
|
1.1
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Gross margin
|
|
|
66.8
|
%
|
|
|
66.8
|
%
|
|
|
66.7
|
%
|
|
|
66.8
|
%
|
|
Operating margin
|
|
|
23.9
|
%
|
|
|
24.0
|
%
|
|
|
23.8
|
%
|
|
|
24.0
|
%
|
|
Diluted earnings per share
|
|
$
|
3.25
|
|
|
$
|
3.12
|
|
|
$
|
3.19
|
|
|
$
|
3.08
|
|
|
EBITDA
|
|
|
26.4
|
%
|
|
|
30.5
|
%
|
|
|
26.4
|
%
|
|
|
30.4
|
%
|
|
Estimated tax rate
|
|
|
19.9
|
%
|
|
|
23.2
|
%
|
|
|
19.8
|
%
|
|
|
23.2
|
%
|
|
______________
|
| (1) |
|
Updated guidance provided May 6, 2019. Prior guidance provided
February 26, 2019.
|
-
Total revenue, including royalty and other revenue, increasing to
$919.1 million;
-
Product revenue increasing 10.6% to $918.0 million, or 11.4% on a
constant currency basis;
-
GAAP diluted earnings per share increasing to $3.25;
-
Non-GAAP diluted earnings per share increasing 17.7% to $3.12; and
-
Included in our full year revenue guidance is approximately $6.5
million of year-over-year currency headwinds.
Impact of Adoption of New Lease Accounting Standard
Effective December 30, 2018, we adopted Accounting Standards
Codification (ASC) Topic 842, Leases (ASC 842). Our adoption of
ASC 842 generally resulted in (a) the recognition of lessee right-of-use
(ROU) assets for the right to use assets subject to operating leases;
(b) the recognition of lessee lease liabilities for our obligation to
make payments under operating leases; and (c) the acceleration of when
we recognize certain revenue and costs as a lessor of equipment provided
to end-user hospitals at no up-front charge under deferred equipment
agreements with fixed multi-year sensor purchase commitments. For
additional information with respect to the impact of the adoption of
this new accounting standard, please reference Note 2 to our condensed
consolidated financial statements that will be included in Part I, Item
1 of our Quarterly Report on Form 10-Q for the quarter ended March 30,
2019, once filed with the Securities and Exchange Commission (SEC) and
Exhibit 99.3 that was included in our Current Report on Form 8-K that
was filed with the SEC today.
Supplementary Non-GAAP Financial Information
For additional non-GAAP financial details, please visit the Investor
Relations section of the Company’s website at www.masimo.com
to access Supplementary Financial Information.
Non-GAAP Financial Measures
The non-GAAP financial measures contained herein are a supplement to the
corresponding financial measures prepared in accordance with U.S. GAAP.
The non-GAAP financial measures presented exclude the items described
below. Management believes that adjustments for these items assist
investors in making comparisons of period-to-period operating results.
Furthermore, management also believes that these items are not
indicative of the Company’s on-going core operating performance. These
non-GAAP financial measures have certain limitations in that they do not
reflect all of the costs associated with the operations of the Company’s
business as determined in accordance with GAAP.
Therefore, investors should consider non-GAAP financial measures in
addition to, and not as a substitute for, or as superior to, measures of
financial performance prepared in accordance with GAAP. The non-GAAP
financial measures presented by the Company may be different from the
non-GAAP financial measures used by other companies.
The Company has presented the following non-GAAP measures to assist
investors in understanding the Company’s core net operating results on
an on-going basis: (i) constant currency product revenue growth %, (ii)
non-GAAP net income, (iii) non-GAAP diluted earnings per share, (iv)
non-GAAP gross profit/margin, (v) non-GAAP operating income/margin, (vi)
non-GAAP product net income, (vii) non-GAAP product diluted earnings per
share, (viii) non-GAAP product gross profit/margin, (ix) non-GAAP
product operating income/margin and (x) adjusted EBITDA. These non-GAAP
financial measures may also assist investors in making comparisons of
the Company’s core operating results with those of other companies.
Management believes non-GAAP product revenue growth percentage (%),
non-GAAP gross profit, non-GAAP operating income, non-GAAP net income,
non-GAAP net income per diluted share and adjusted EBITDA are important
measures in the evaluation of the Company’s performance and uses these
measures to better understand and evaluate our business.
The non-GAAP financial measures reflect adjustments for the following
items, as well as the related income tax effects thereof:
Constant currency adjustments.
Some of our sales agreements with foreign customers provide for payment
in currencies other than the U.S. Dollar. These foreign currency
revenues, when converted into U.S. Dollars, can vary significantly from
period to period depending on the average and quarter-end exchange rates
during a respective period. We believe that comparing these foreign
currency denominated revenues by holding the exchange rates constant
with the prior year period is useful to management and investors in
evaluating our product revenue growth rates on a period-to-period basis.
We anticipate that fluctuations in foreign exchange rates and the
related constant currency adjustments for calculation of our product
revenue growth rate will continue to occur in future periods.
Royalty and other revenue, net of related costs.
We derive royalty and other revenue, net of related costs, from certain
non-recurring contractual arrangements that we do not expect to continue
in the future. We believe the exclusion of royalty and other revenue,
net of related costs, associated with these non-recurring revenue
streams is useful to management and investors in evaluating the
performance of our ongoing operations on a period-to-period basis.
Acquisition-related costs, including
depreciation and amortization.
Depreciation and amortization related to the revaluation of assets and
liabilities (primarily intangible assets, property, plant and equipment
adjustments, inventory revaluation, lease liabilities, etc.) to fair
value through purchase accounting related to value created by the seller
prior to the acquisition rather than ongoing costs of operating our core
business. As a result, we believe that exclusion of these costs in
presenting non-GAAP financial measures provides management and investors
a more effective means of evaluating historical performance and
projected costs and the potential for realizing cost efficiencies within
our core business. Depreciation and amortization related to the
revaluation of acquisition related assets and liabilities will generally
recur in future periods.
Litigation damages, awards and settlements.
In connection with litigation proceedings arising in the course of our
business, we have recorded expenses as a defendant in such proceedings
in the form of damages, as well as gains as a plaintiff in such
proceedings in the form of litigation awards and settlement proceeds;
most recently in connection with our November 2016 settlement agreement
with Koninklijke Philips N.V. We believe that exclusion of these gains
and losses is useful to management and investors in evaluating the
performance of our ongoing operations on a period-to-period basis. In
this regard, we note that these expenses and gains are generally
unrelated to our core business and/or infrequent in nature.
Realized and unrealized gains or losses from
foreign currency transactions.
We are exposed to foreign currency gains or losses on outstanding
foreign currency denominated receivables and payables related to certain
customer sales agreements, product costs and other operating expenses.
As the Company does not actively hedge these currency exposures, changes
in the underlying currency rates relative to the U.S. Dollar may result
in realized and unrealized foreign currency gains and losses between the
time these receivables and payables arise and the time that they are
settled in cash. Since such realized and unrealized foreign currency
gains and losses are the result of macro-economic factors and can vary
significantly from one period to the next, we believe that exclusion of
such realized and unrealized gains and losses are useful to management
and investors in evaluating the performance of our ongoing operations on
a period-to-period basis. Realized and unrealized foreign currency gains
and losses are likely to recur in future periods.
Excess tax benefits from stock-based
compensation.
Current authoritative accounting guidance requires that excess tax
benefits or costs recognized on stock-based compensation expense be
reflected in our provision for income taxes rather than paid-in capital.
Since we cannot control or predict when stock option awards will be
exercised or the price at which such awards will be exercised, the
impact of such guidance can create significant volatility in our
effective tax rate from one period to the next. We believe that
exclusion of these excess tax benefits or costs is useful to management
and investors in evaluating the performance of our ongoing operations on
a period-to-period basis. These excess tax benefits or costs will
generally recur in future periods as long as we continue to issue equity
awards to our employees.
Tax impacts that may not be representative of
the ongoing results of our core operations.
From time-to-time, we may experience significant non-recurring tax
events, such as changes in tax laws and regulations or the derecognition
of uncertain tax positions related to non-recurring transactions due to
the expiration of the statutes of limitations. We believe that exclusion
of such tax charges or benefits is useful to management and investors in
evaluating the performance of our ongoing operations on a
period-to-period basis. In this regard, we note that these tax items are
unrelated to our core business and generally unique and non-recurring in
nature.
First Quarter 2019 Actuals versus First Quarter
2018 Actuals
|
|
|
RECONCILIATION OF GAAP TO NON-GAAP
CONSTANT CURRENCY PRODUCT REVENUE:
|
|
|
Three Months Ended |
| (in thousands, except percentages) |
|
March 30,
2019
|
|
March 31,
2018
|
|
GAAP product revenue
|
|
$
|
230,548
|
|
|
$
|
204,389
|
|
Non-GAAP constant currency adjustments:
|
|
|
|
|
|
Constant currency F/X adjustments
|
|
|
3,049
|
|
|
|
N/A
|
|
Total non-GAAP constant currency adjustments
|
|
|
3,049
|
|
|
|
N/A
|
|
Non-GAAP (constant currency) product revenue
|
|
$
|
233,597
|
|
|
$
|
204,389
|
|
Product revenue growth %:
|
|
|
|
|
|
GAAP
|
|
|
12.8
|
%
|
|
|
|
Non-GAAP (constant currency)
|
|
|
14.3
|
%
|
|
|
|
|
|
RECONCILIATION OF GAAP TO NON-GAAP NET
INCOME AND NET INCOME PER DILUTED SHARE:
|
|
|
Three Months Ended |
|
|
March 30,
2019
|
|
March 31,
2018
|
| (in thousands, except per share amounts) |
|
|
$ |
|
|
Per Diluted
Share
|
|
|
$ |
|
|
Per Diluted
Share
|
|
GAAP net income
|
|
$
|
49,322
|
|
|
$
|
0.87
|
|
|
$
|
45,630
|
|
|
$
|
0.82
|
|
|
Non-GAAP adjustments:
|
|
|
|
|
|
|
|
|
|
Royalty and other revenue, net of related costs
|
|
|
(1,048
|
)
|
|
|
(0.02
|
)
|
|
|
(8,390
|
)
|
|
|
(0.15
|
)
|
|
Acquisition-related depreciation and amortization
|
|
|
361
|
|
|
|
—
|
|
|
|
360
|
|
|
|
0.01
|
|
|
Non-operating other (income) expense
|
|
|
(534
|
)
|
|
|
(0.01
|
)
|
|
|
(1,113
|
)
|
|
|
(0.02
|
)
|
|
Tax impact of pre-tax non-GAAP adjustments above
|
|
|
362
|
|
|
|
0.01
|
|
|
|
2,101
|
|
|
|
0.04
|
|
|
Excess tax benefits from stock-based compensation
|
|
|
(3,432
|
)
|
|
|
(0.06
|
)
|
|
|
(3,148
|
)
|
|
|
(0.06
|
)
|
|
2017 U.S. Tax Reform
|
|
|
—
|
|
|
|
—
|
|
|
|
16
|
|
|
|
—
|
|
|
Total non-GAAP adjustments
|
|
|
(4,291
|
)
|
|
|
(0.08
|
)
|
|
|
(10,174
|
)
|
|
|
(0.18
|
)
|
|
Non-GAAP net income
|
|
$
|
45,031
|
|
|
$
|
0.79
|
|
|
$
|
35,456
|
|
|
$
|
0.64
|
|
|
Weighted average shares outstanding - diluted
|
|
|
|
|
56,799
|
|
|
|
|
|
55,496
|
|
|
|
|
RECONCILIATION OF GAAP TO NON-GAAP
OPERATING MARGIN
|
|
|
Three Months Ended |
|
|
March 30,
2019
|
|
March 31,
2018
|
| (in thousands, except percentages) |
|
|
$ |
|
|
|
$ |
|
|
GAAP operating income/margin
|
|
$
|
56,023
|
|
|
$
|
53,885
|
|
|
Non-GAAP adjustments:
|
|
|
|
|
|
Royalty and other revenue, net of related costs
|
|
|
(1,048
|
)
|
|
|
(8,390
|
)
|
|
Acquisition-related depreciation and amortization
|
|
|
361
|
|
|
|
360
|
|
|
Total non-GAAP adjustments
|
|
|
(687
|
)
|
|
|
(8,030
|
)
|
|
Non-GAAP operating income/margin
|
|
$
|
55,336
|
|
|
$
|
45,855
|
|
|
GAAP operating income/margin %
|
|
|
24.2
|
%
|
|
|
25.3
|
%
|
|
Non-GAAP operating income/margin %(1) |
|
|
24.0
|
%
|
|
|
22.4
|
%
|
|
|
Full Year 2019 Guidance versus Full Year 2018
Actuals
|
|
|
RECONCILIATION OF GAAP PRODUCT REVENUE
GROWTH % TO
CONSTANT CURRENCY PRODUCT REVENUE GROWTH
%:
|
|
|
|
Full Year 2019
Updated
Guidance(2)
|
|
Full Year 2018
Actuals
|
|
GAAP product revenue
|
|
$
|
918,000
|
|
|
$
|
829,874
|
|
Non-GAAP constant currency adjustments:
|
|
|
|
|
|
Constant currency F/X adjustments
|
|
|
6,500
|
|
|
|
N/A
|
|
Total non-GAAP constant currency adjustments
|
|
|
6,500
|
|
|
|
N/A
|
|
Non-GAAP (constant currency) product revenue
|
|
$
|
924,500
|
|
|
$
|
829,874
|
|
Product revenue growth %:
|
|
|
|
|
|
GAAP
|
|
|
10.6
|
%
|
|
|
|
Non-GAAP (constant currency)
|
|
|
11.4
|
%
|
|
|
|
__________________
|
| (1) |
|
Calculated based upon product revenue versus total revenue.
|
| (2) |
|
Updated guidance provided May 6, 2019. Prior guidance provided
February 26, 2019
|
|
|
|
RECONCILIATION OF GAAP TO NON-GAAP NET
INCOME AND
NET INCOME PER DILUTED SHARE:
|
|
|
|
|
|
|
|
|
|
Full Year 2019
Updated Guidance(2)
|
|
Full Year 2018
Actuals
|
| (in thousands, except per share amounts) |
|
|
$ |
|
|
Per Diluted
Share
|
|
|
$ |
|
|
Per Diluted
Share
|
|
GAAP net income
|
|
$
|
186,925
|
|
|
$
|
3.25
|
|
|
$
|
193,543
|
|
|
$
|
3.45
|
|
|
Non-GAAP adjustments:
|
|
|
|
|
|
|
|
|
|
Royalty and other revenue, net of related costs
|
|
|
(1,048
|
)
|
|
|
(0.02
|
)
|
|
|
(27,704
|
)
|
|
|
(0.50
|
)
|
|
Acquisition-related depreciation and amortization
|
|
|
1,430
|
|
|
|
0.03
|
|
|
|
1,442
|
|
|
|
0.02
|
|
|
Litigation damages, awards and settlements
|
|
|
—
|
|
|
|
—
|
|
|
|
425
|
|
|
|
0.01
|
|
|
Non-operating other (income) expense
|
|
|
—
|
|
|
|
—
|
|
|
|
2,027
|
|
|
|
0.03
|
|
|
Tax impact of pre-tax non-GAAP adjustments above
|
|
|
182
|
|
|
|
—
|
|
|
|
5,531
|
|
|
|
0.11
|
|
|
Excess tax benefits from stock-based compensation
|
|
|
(8,032
|
)
|
|
|
(0.14
|
)
|
|
|
(22,036
|
)
|
|
|
(0.39
|
)
|
|
Expiration of certain statutes of limitations related to unique and
non-recurring tax positions
|
|
|
—
|
|
|
|
—
|
|
|
|
(4,169
|
)
|
|
|
(0.07
|
)
|
|
2017 U.S. Tax Reform
|
|
|
—
|
|
|
|
—
|
|
|
|
(675
|
)
|
|
|
(0.01
|
)
|
|
Total non-GAAP adjustments
|
|
|
(7,468
|
)
|
|
|
(0.13
|
)
|
|
|
(45,159
|
)
|
|
|
(0.80
|
)
|
|
Non-GAAP net income
|
|
$
|
179,457
|
|
|
$
|
3.12
|
|
|
$
|
148,384
|
|
|
$
|
2.65
|
|
|
Weighted average shares outstanding - diluted
|
|
|
|
|
57,599
|
|
|
|
|
|
56,039
|
|
|
|
|
RECONCILIATION OF GAAP TO NON-GAAP GROSS
PROFIT AND OPERATING MARGIN:
|
|
|
|
|
|
|
|
Full Year 2019
Updated
Guidance(2)
|
|
Full Year 2018
Actuals
|
| (in thousands, except percentages) |
|
|
$ |
|
|
|
$ |
|
|
GAAP gross margin
|
|
|
613,814
|
|
|
|
574,892
|
|
|
Non-GAAP adjustments:
|
|
|
|
|
|
Royalty and other revenue, net of related costs
|
|
|
(1,048
|
)
|
|
|
(27,704
|
)
|
|
Acquisition-related depreciation and amortization
|
|
|
458
|
|
|
|
458
|
|
|
Total non-GAAP adjustments
|
|
|
(590
|
)
|
|
|
(27,246
|
)
|
|
Non-GAAP gross margin
|
|
$
|
613,224
|
|
|
$
|
547,646
|
|
|
GAAP gross margin %
|
|
|
66.8
|
%
|
|
|
67.0
|
%
|
|
Non-GAAP gross margin %(1) |
|
|
66.8
|
%
|
|
|
66.0
|
%
|
|
|
|
GAAP operating income/margin
|
|
|
219,938
|
|
|
|
208,044
|
|
|
Non-GAAP adjustments:
|
|
|
|
|
|
Royalty and other revenue, net of related costs
|
|
|
(1,048
|
)
|
|
|
(27,704
|
)
|
|
Acquisition-related depreciation and amortization
|
|
|
1,430
|
|
|
|
1,442
|
|
|
Litigation damages, awards and settlements
|
|
|
—
|
|
|
|
425
|
|
|
Total non-GAAP adjustments
|
|
|
382
|
|
|
|
(25,837
|
)
|
|
Non-GAAP operating income/margin
|
|
$
|
220,320
|
|
|
$
|
182,207
|
|
|
GAAP operating income/margin %
|
|
|
23.9
|
%
|
|
|
24.2
|
%
|
|
Non-GAAP operating income/margin %(1) |
|
|
24.0
|
%
|
|
|
22.0
|
%
|
|
__________________
|
| (1) |
|
Calculated based upon product revenue versus total revenue.
|
| (2) |
|
Updated guidance provided May 6, 2019. Prior guidance provided
February 26, 2019
|
|
|
|
RECONCILIATION OF EBITDA TO ADJUSTED
EBITDA:
|
|
|
|
|
|
|
|
|
|
Full Year 2019
Updated Guidance(2)
|
|
Full Year 2018
Actuals
|
| (in thousands, except percentages) |
|
|
$ |
|
|
% of Revenue
|
|
|
$ |
|
|
% of Revenue |
|
GAAP net income
|
|
$
|
186,925
|
|
|
20.3
|
%
|
|
$
|
193,543
|
|
|
22.5
|
%
|
|
Other (income)/expense(3) |
|
|
(13,405
|
)
|
|
(1.5
|
)
|
|
|
(5,732
|
)
|
|
(0.7
|
)
|
|
Provision for income taxes
|
|
|
46,419
|
|
|
5.1
|
|
|
|
20,233
|
|
|
2.4
|
|
|
Depreciation and amortization
|
|
|
22,773
|
|
|
2.5
|
|
|
|
21,127
|
|
|
2.5
|
|
|
EBITDA
|
|
|
242,712
|
|
|
26.4
|
|
|
|
229,171
|
|
|
26.7
|
|
|
Add: Non-cash stock-based compensation expense
|
|
|
37,174
|
|
|
4.1
|
|
|
|
27,416
|
|
|
3.2
|
|
|
Add: Litigation damages, awards and settlements
|
|
|
—
|
|
|
—
|
|
|
|
425
|
|
|
—
|
|
|
Adjusted EBITDA
|
|
$
|
279,886
|
|
|
30.5
|
%
|
|
$
|
257,012
|
|
|
29.9
|
%
|
|
__________________
|
| (2) |
|
Updated guidance provided May 6, 2019. Prior guidance provided
February 26, 2019
|
| (3) |
|
Other (income)/expense consists primarily of interest
(income)/expense and net foreign currency (gains)/losses.
|
Conference Call
Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET)
to discuss the results. A live webcast of the call will be available
online from the investor relations page of the Company’s website at www.masimo.com.
The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706)
758-3929 for international callers. The reservation code for both
dial-in numbers is 2399557. After the live webcast, the call will be
available on Masimo’s website through June 6, 2019. In addition, a
telephonic replay of the call will be available through May 13, 2019.
The replay dial-in numbers are (855) 859-2056 for domestic callers and
+1 (404) 537-3406 for international callers. Please use reservation code
2399557.
About Masimo
Masimo (Nasdaq: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the Company debuted Masimo SET®
Measure-through Motion and Low Perfusion® pulse oximetry,
which has been shown in multiple studies to significantly reduce false
alarms and accurately monitor for true alarms. Masimo SET® is
estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood constituents
that previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability
Index (PVi®) and more recently, Oxygen Reserve Index (ORi™),
in addition to SpO2, pulse rate and perfusion index (PI). In 2014,
Masimo introduced Root™, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect® (MOC-9®)
interface. Masimo is also taking an active leadership role in mobile
health applications (mHealth) with products such as the Radius-7®
wearable patient monitor and the MightySat™ fingertip pulse
oximeter. Additional information about Masimo and its products may be
found at www.masimo.com.
Forward-Looking Statements
All statements other than statements of historical facts included in
this press release that address activities, events or developments that
we expect, believe or anticipate will or may occur in the future are
forward-looking statements including, in particular, the statements
about our expectations for full fiscal year GAAP and non-GAAP 2019 total
revenue, product revenue, royalty and other revenues, gross margin,
operating margin, diluted earnings per share, EBITDA, estimated tax rate
and our long-term outlook; demand for our products; anticipated revenue
and earnings growth; our financial condition, results of operations and
business generally; expectations regarding our ability to design and
deliver innovative new noninvasive technologies and reduce the cost of
care; and demand for our technologies. These forward-looking statements
are based on management’s current expectations and beliefs and are
subject to uncertainties and factors, all of which are difficult to
predict and many of which are beyond our control and could cause actual
results to differ materially and adversely from those described in the
forward-looking statements. These risks include, but are not limited to,
those related to: our dependence on Masimo SET® and Masimo
rainbow SET™ products and technologies for substantially all
of our revenue; any failure in protecting our intellectual property
exposure to competitors’ assertions of intellectual property claims; the
highly competitive nature of the markets in which we sell our products
and technologies; any failure to continue developing innovative products
and technologies; the lack of acceptance of any of our current or future
products and technologies; obtaining regulatory approval of our current
and future products and technologies; the risk that the implementation
of our international realignment will not continue to produce
anticipated operational and financial benefits, including a continued
lower effective tax rate; the loss of our customers; the failure to
retain and recruit senior management; product liability claims exposure;
a failure to obtain expected returns from the amount of intangible
assets we have recorded; the maintenance of our brand; the amount and
type of equity awards that we may grant to employees and service
providers in the future; our ongoing litigation and related matters; and
other factors discussed in the “Risk Factors” section of our most recent
periodic reports filed with the Securities and Exchange Commission
(“SEC”), including our most recent Form 10-K and Form 10-Q, all of which
you may obtain for free on the SEC’s website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof, even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required under
applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care... by Taking Noninvasive Monitoring to New
Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI
are trademarks or registered trademarks of Masimo Corporation.
| MASIMO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
|
|
|
|
|
March 30,
2019
|
|
December 29,
2018
|
| ASSETS |
|
|
|
|
|
Current assets
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
412,861
|
|
|
$
|
552,490
|
|
|
Short-term investments
|
|
|
180,000
|
|
|
|
—
|
|
|
Accounts receivable, net of allowance for doubtful accounts
|
|
|
117,822
|
|
|
|
109,629
|
|
|
Inventories
|
|
|
93,259
|
|
|
|
94,732
|
|
|
Other current assets
|
|
|
46,355
|
|
|
|
29,227
|
|
|
Total current assets
|
|
|
850,297
|
|
|
|
786,078
|
|
|
Lease receivable, noncurrent
|
|
|
41,149
|
|
|
|
—
|
|
|
Deferred costs and other contract assets
|
|
|
15,599
|
|
|
|
126,105
|
|
|
Property and equipment, net
|
|
|
167,288
|
|
|
|
165,972
|
|
|
Intangible assets, net
|
|
|
27,830
|
|
|
|
27,924
|
|
|
Goodwill
|
|
|
22,376
|
|
|
|
23,297
|
|
|
Deferred tax assets
|
|
|
30,464
|
|
|
|
21,210
|
|
|
Other non-current assets
|
|
|
24,373
|
|
|
|
4,232
|
|
|
Total assets
|
|
$
|
1,179,376
|
|
|
$
|
1,154,818
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
Accounts payable
|
|
$
|
32,970
|
|
|
$
|
40,388
|
|
|
Accrued compensation
|
|
|
30,040
|
|
|
|
49,486
|
|
|
Other current liabilities
|
|
|
35,470
|
|
|
|
24,627
|
|
|
Deferred revenue and other contract-related liabilities, current
|
|
|
22,677
|
|
|
|
33,106
|
|
|
Total current liabilities
|
|
|
121,157
|
|
|
|
147,607
|
|
|
Other non-current liabilities
|
|
|
53,143
|
|
|
|
38,146
|
|
|
Total liabilities
|
|
|
174,300
|
|
|
|
185,753
|
|
|
Commitments and contingencies
|
|
|
|
|
|
Stockholders’ equity
|
|
|
|
|
|
Common stock
|
|
|
53
|
|
|
|
53
|
|
|
Treasury stock
|
|
|
(489,026
|
)
|
|
|
(489,026
|
)
|
|
Additional paid-in capital
|
|
|
547,225
|
|
|
|
533,164
|
|
|
Accumulated other comprehensive loss
|
|
|
(6,776
|
)
|
|
|
(6,199
|
)
|
|
Retained earnings
|
|
|
953,600
|
|
|
|
931,073
|
|
|
Total stockholders’ equity
|
|
|
1,005,076
|
|
|
|
969,065
|
|
|
Total liabilities and stockholders’ equity
|
|
$
|
1,179,376
|
|
|
$
|
1,154,818
|
|
|
|
| MASIMO CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share amounts)
|
|
|
|
|
Three Months Ended |
|
|
March 30,
2019
|
|
March 31,
2018
|
|
Revenue:
|
|
|
|
|
|
Product
|
|
$
|
230,548
|
|
$
|
204,389
|
|
Royalty and other revenue
|
|
|
1,116
|
|
|
8,564
|
|
Total revenue
|
|
|
231,664
|
|
|
212,953
|
|
Cost of goods sold
|
|
|
80,022
|
|
|
69,292
|
|
Gross profit
|
|
|
151,642
|
|
|
143,661
|
|
Operating expenses:
|
|
|
|
|
|
Selling, general and administrative
|
|
|
74,204
|
|
|
70,217
|
|
Research and development
|
|
|
21,415
|
|
|
19,559
|
|
Total operating expenses
|
|
|
95,619
|
|
|
89,776
|
|
Operating income
|
|
|
56,023
|
|
|
53,885
|
|
Non-operating income
|
|
|
3,886
|
|
|
1,647
|
|
Income before provision for income taxes
|
|
|
59,909
|
|
|
55,532
|
|
Provision for income taxes
|
|
|
10,587
|
|
|
9,902
|
|
Net income
|
|
$
|
49,322
|
|
$
|
45,630
|
|
|
|
|
|
|
Net income per share:
|
|
|
|
|
|
Basic
|
|
$
|
0.93
|
|
$
|
0.88
|
|
Diluted
|
|
$
|
0.87
|
|
$
|
0.82
|
|
|
|
|
|
|
Weighted-average shares used in per share calculations:
|
|
|
|
|
|
Basic
|
|
|
53,210
|
|
|
51,709
|
|
Diluted
|
|
|
56,799
|
|
|
55,496
|
|
|
|
The following table presents details of the stock-based
compensation expense that is included in each functional line item
in the condensed consolidated statements of operations (in
thousands):
|
|
|
|
|
Three Months Ended |
|
|
March 30,
2019
|
|
March 31,
2018
|
|
Cost of goods sold
|
|
$
|
97
|
|
$
|
78
|
|
Selling, general and administrative
|
|
|
5,725
|
|
|
4,036
|
|
Research and development
|
|
|
1,495
|
|
|
1,218
|
|
Total
|
|
$
|
7,317
|
|
$
|
5,332
|
|
|
| MASIMO CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)
|
|
|
|
|
Three Months Ended |
|
|
March 30,
2019
|
|
March 31,
2018
|
| Cash flows from operating activities: |
|
|
|
|
|
Net income
|
|
$
|
49,322
|
|
|
$
|
45,630
|
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
Depreciation and amortization
|
|
|
5,419
|
|
|
|
5,241
|
|
|
Stock-based compensation
|
|
|
7,317
|
|
|
|
5,332
|
|
|
Loss on disposal of property, equipment and intangibles
|
|
|
65
|
|
|
|
429
|
|
|
Provision from doubtful accounts
|
|
|
234
|
|
|
|
(394
|
)
|
|
Benefit from deferred income taxes
|
|
|
(31
|
)
|
|
|
—
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
(Increase) decrease in accounts receivable
|
|
|
(8,531
|
)
|
|
|
17,776
|
|
|
Decrease in inventories
|
|
|
1,357
|
|
|
|
1,139
|
|
|
Decrease (increase) in other current assets
|
|
|
3,043
|
|
|
|
(204
|
)
|
|
Increase in lease receivable, net
|
|
|
(3,104
|
)
|
|
|
—
|
|
|
Decrease (increase) in deferred costs and other contract assets
|
|
|
7,120
|
|
|
|
(5,706
|
)
|
|
(Increase) decrease in other non-current assets
|
|
|
(115
|
)
|
|
|
644
|
|
|
(Decrease) increase in accounts payable
|
|
|
(6,097
|
)
|
|
|
2,363
|
|
|
Decrease in accrued compensation
|
|
|
(19,364
|
)
|
|
|
(11,074
|
)
|
|
(Decrease) increase in accrued liabilities
|
|
|
(2,736
|
)
|
|
|
2,193
|
|
|
Increase in income tax payable
|
|
|
5,566
|
|
|
|
6,318
|
|
|
Increase in deferred revenue and other contract-related liabilities
|
|
|
2,377
|
|
|
|
2,381
|
|
|
Increase (decrease) in other non-current liabilities
|
|
|
626
|
|
|
|
(73
|
)
|
| Net cash provided by operating activities |
|
|
42,468
|
|
|
|
71,995
|
|
| Cash flows from investing activities: |
|
|
|
|
|
Purchases of short-term investments
|
|
|
(180,000
|
)
|
|
|
—
|
|
|
Purchases of property and equipment, net
|
|
|
(6,963
|
)
|
|
|
(3,788
|
)
|
|
Increase in intangible assets
|
|
|
(1,040
|
)
|
|
|
(3,583
|
)
|
| Net cash used in investing activities |
|
|
(188,003
|
)
|
|
|
(7,371
|
)
|
| Cash flows from financing activities: |
|
|
|
|
|
Proceeds from issuance of common stock
|
|
|
6,288
|
|
|
|
8,415
|
|
|
Payroll tax withholdings on behalf of employees for vested equity
awards
|
|
|
(123
|
)
|
|
|
(168
|
)
|
|
Repurchases of common stock
|
|
|
—
|
|
|
|
(18,479
|
)
|
| Net cash provided by (used in) financing activities |
|
|
6,165
|
|
|
|
(10,232
|
)
|
|
Effect of foreign currency exchange rates on cash
|
|
|
(261
|
)
|
|
|
(225
|
)
|
|
Net (decrease) increase in cash, cash equivalents, and restricted
cash
|
|
|
(139,631
|
)
|
|
|
54,167
|
|
|
Cash, cash equivalents and restricted cash at beginning of period
|
|
|
552,641
|
|
|
|
315,483
|
|
|
Cash, cash equivalents and restricted cash at end of period
|
|
$
|
413,010
|
|
|
$
|
369,650
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005671/en/
Source: Masimo
Investor Contact: Eli Kammerman
(949) 297-7077
ekammerman@masimo.com
Media Contact: Irene Paigah
(858) 859-7001
irenep@masimo.com